No results for ‘’
Dr Reddys Laboratories Ltd
₹1268.50
(0.56%)
Sat, 13 Jun 2026, 10:56 am
Health Technology
Pharmaceuticals: Major
24.5KDr Reddys Laboratories Enterprise Value (EV)
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 74.48 | 12.02 | 22.82 | 0 | 61.71 | 25.23 | 20.98 | 17.94 | 20.32 | 26.88 | 25.94 | 36.52 | 35.29 | 24.53 | 26.55 | 43.57 | 30.39 | 17.06 | 18.43 | 16.88 |
| Price to book ratio | 5.27 | 3.06 | 2.21 | 2.33 | 5.71 | 6.03 | 5.19 | 4.12 | 4.80 | 5.34 | 4.03 | 3.52 | 2.73 | 3.28 | 3.33 | 4.32 | 3.75 | 3.33 | 3.66 | 2.86 |
| Price to sales ratio | 4.62 | 1.78 | 2 | 1.20 | 3.08 | 3.73 | 3.09 | 2.59 | 3.31 | 4.02 | 3.36 | 3.12 | 2.44 | 3 | 2.97 | 3.96 | 3.34 | 3.13 | 3.68 | 2.93 |
| Price to cash flow ratio | 94.24 | 10.06 | 20.72 | 15.65 | 11.77 | 35.84 | 19.47 | 23.33 | 22.67 | 24.08 | 12.48 | 20.72 | 20.23 | 16.54 | 17.70 | 21.09 | 25.91 | 13.30 | 22.83 | 20.60 |
| Enterprise value | 13064Cr | 12242Cr | 11221Cr | 9713Cr | 22512Cr | 29552Cr | 31333Cr | 31517Cr | 44777Cr | 59879Cr | 51257Cr | 47041Cr | 37572Cr | 47467Cr | 51406Cr | 74675Cr | 70563Cr | 72064Cr | 96466Cr | 94698Cr |
| Enterprise value to EBITDA ratio | 40.69 | 7.39 | 13.62 | 6.66 | 15.64 | 18.87 | 13.20 | 12.59 | 14.34 | 17.62 | 13.12 | 19.47 | 16.41 | 14.94 | 12.50 | 16.66 | 15.24 | 11.11 | 12.26 | 10.94 |
| Debt to equity ratio | 1.51 | 0.62 | 0.44 | 0.57 | 0.39 | 0.51 | 0.56 | 0.51 | 0.49 | 0.39 | 0.26 | 0.40 | 0.40 | 0.27 | 0.14 | 0.18 | 0.18 | 0.06 | 0.07 | 0.14 |
| Return on equity % | 7.32 | 31.85 | 10.32 | -22.86 | 9.63 | 26.36 | 27.58 | 25.77 | 26.26 | 21.95 | 16.70 | 9.54 | 7.83 | 14.10 | 13.21 | 10.51 | 12.96 | 21.38 | 21.77 | 18.42 |
Dr Reddys Laboratories Ltd Enterprise Value
The Dr Reddys Laboratories Ltd Enterprise Value is a key financial metric used by investors to evaluate Dr Reddys Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Dr Reddys Laboratories Ltd Enterprise Value helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Dr Reddys Laboratories Ltd (NSE: DRREDDY, BSE: 500124) is currently trading at ₹1268.50, with a market capitalization of ₹106429.04Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Dr Reddys Laboratories Ltd Enterprise Value is essential for fundamental analysis.
Dr Reddys Laboratories Ltd Enterprise Value Current Value
The current Dr Reddys Laboratories Ltd Enterprise Value stands at 94698Cr.
The Dr Reddys Laboratories Ltd Enterprise Value has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Dr Reddys Laboratories Ltd Enterprise Value Historical Trend
The Dr Reddys Laboratories Ltd Enterprise Value has shown the following historical trend:
- 2024: 94698Cr
- 2023: 96466Cr
- 2022: 72064Cr
- 2021: 70563Cr
- 2020: 74675Cr
The decline in Dr Reddys Laboratories Ltd Enterprise Value indicates improving financial efficiency or better earnings growth.
What Dr Reddys Laboratories Ltd Enterprise Value Indicates for Investors
The Dr Reddys Laboratories Ltd Enterprise Value plays a crucial role in understanding the company's financial health and valuation.
This ratio is an important metric used in fundamental analysis of Dr Reddys Laboratories Ltd.
Dr Reddys Laboratories Ltd Enterprise Value Analysis Summary
The Dr Reddys Laboratories Ltd Enterprise Value remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Dr Reddys Laboratories Ltd Enterprise Value should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Dr Reddys Laboratories Ltd Enterprise Value helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.